Cellectar reports durable responses to iopofosine I 131 in Phase 2b Waldenström macroglobulinemia trial
CLRB•Updated Phase 2b CLOVER WaM results show durable responses in heavily pretreated patients, with longer-lasting responses among those who had received only two prior treatment lines. Cellectar plans a Phase 3 trial, first-patient dosing in the first quarter of 2027 and an FDA accelerated-approval filing in the first half of 2027.
1. Trial results and plans
Cellectar Biosciences said updated Phase 2b CLOVER WaM results show durable responses to iopofosine I 131 in heavily pretreated patients with Waldenström macroglobulinemia, with longer-lasting responses following only two prior treatment lines. The company plans a Phase 3 confirmatory trial comparing the drug with rituximab-cyclophosphamide-dexamethasone in patients previously treated with a Bruton tyrosine kinase inhibitor; first-patient dosing is targeted for the first quarter of 2027, and an FDA filing seeking accelerated approval remains planned for the first half of 2027.
2. Conference presentations
Cellectar will present three iopofosine I 131 posters in Waldenström macroglobulinemia at the American Society of Hematology meeting from December 12 to 15, 2026.
